Drugs / ALTO-203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06391593 | Mar 2024 → Apr 2025 | atypical depressive disorder, major depressive disorder | Alto Neuroscience | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALTO-203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06391593 ↗ |
| Route | Oral | “ALTO-203 25 μg, administered orally, once daily for 28 days” NCT06391593 ↗ |